Infigratinib - Uses, Dosage, Side Effects, Interaction

Infigratinib is a FGF receptor kinase inhibitor that is used in the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma. Infigratinib is associated with transient and usually mild elevations in serum aminotransferase during therapy, but has not been convincingly linked to cases of clinically apparent liver injury.

Infigratinib is an orally bioavailable pan inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases which may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.

Infigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumor growth. Cholangiocarcinoma is the most common primary malignancy affecting the biliary tract and the second most common primary hepatic malignancy. Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. On May 28, 2021, the FDA granted accelerated approval to infigratinib – under the market name Truseltiq – for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test. This approval follows [pemigatinib], another FGFR inhibitor approved by the FDA for the same therapeutic indication.

Infigratinib Phosphate is the phosphate salt form of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of angiogenesis and cell proliferation, and the induction of cell death in tumors with activating FGFR amplifications, mutations, or fusions. FGFRs are a family of receptor tyrosine kinases that are involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival. Activating FGFR amplifications, mutations, or fusions occur in various cancer cell types.

Infigratinib Mesylate is the mesylate salt of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with potential antiangiogenic and antineoplastic activities. Upon administration, infigratinib selectively binds to and inhibits the activities of FGFRs, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation, and the induction of tumor cell death. FGFRs are a family of receptor tyrosine kinases that may be upregulated in various tumor cell types and may be involved in tumor cell differentiation and proliferation, tumor angiogenesis, and tumor cell survival.

Mechanism of Action

Fibroblast growth factor receptors (FGFRs) are tyrosine kinase receptors that play a role in cell proliferation, differentiation, migration, survival, and angiogenesis. Upon binding of extracellular signals, primarily fibroblast growth factors, FGFR dimerizes to promote the phosphorylation of downstream molecules and activation of the Ras-mitogen-activated protein kinase (MAPK) pathway. In some cancers, the FGFR signaling pathway is aberrant and disrupted, leading to unregulated cell proliferation and growth, including malignant cells. Alterations in the FGFR receptors, including mutations, amplifications, and fusions, are associated with a wide array of neoplasms, including prostate, urothelial, ovarian, breast, and liver cancer. In particular, FGFR2 fusion is closely related to intrahepatic cholangiocarcinoma: recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma exhibited gene rearrangements resulting in FGFR2 fusion proteins. Alterations in FGFR in tumors can lead to constitutive FGFR signaling, supporting the proliferation and survival of malignant cells. Infigratinib is a reversible, non-competitive inhibitor of all four FGFR subtypes – FGFR1, FGFR2, FGFR3, and FGFR4 – that blocks FGFR signaling and inhibits cell proliferation in cancer cell lines with activating FGFR amplification, mutations, or fusions. Out of the four FGFR subtypes, infigratinib has the highest affinity for FGFR1, FGFR2, and FGFR3. Infigratinib binds to the allosteric site between the two kinase lobes of the FGFR – or more specifically, to the ATP-binding cleft. Binding to this cleft prevents autophosphorylation of the receptor and blocks downstream signaling cascades that would otherwise activate MAPK.

Infigratinib is an anti-tumour agent that works to suppress tumour growth in cholangiocarcinoma. It exhibits anti-tumour activity in mouse and rat xenograft models of human tumours with activating FGFR2 or FGFR3 alterations, such as FGFR2-TTC28 or FGFR2-TRA2B fusions. In clinical trials, patients with cholangiocarcinoma who were treated with infigratinib had an overall response rate of 23% – where one patient had a complete response – and a duration of response of 5.5 months, with a range between 0.03 and 28.3 months. Some patients with cancers with FGFR mutations display intrinsic resistance to infigratinib, leading to negligible therapeutic efficacy: investigations are ongoing to target molecular pathways to combat drug resistance.

Indications

Infigratinib is indicated for the treatment of previously treated, unresectable locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.
Treatment of cholangiocarcinoma
Treatment of achondroplasia
Infigratinib is an FGF receptor kinase inhibitor that is used in the treatment of unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma.
Infigratinib is an FGFR inhibitor used to treat locally advanced or metastatic cholangiocarcinoma in adults with a fibroblast growth factor receptor 2 (FGFR2) rearrangement.
Unresectable, locally advanced Cholangiocarcinomas
Unresectable, metastatic Cholangiocarcinomas

Use in Cancer

Infigratinib phosphate is approved to treat:

Cholangiocarcinoma (bile duct cancer) has spread and cannot be removed with surgery. It is used in adults whose cancer has been treated and has an FGFR2 gene fusion or other change in the structure of the FGFR2 gene.

Infigratinib phosphate is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that it provides a clinical benefit in these patients.

Infigratinib phosphate is also being studied in the treatment of other types of cancer.

Contraindications

high amount of phosphate in the blood
liver problems
pregnancy
a patient who is producing milk and breastfeeding
chronic kidney disease stage 3B (moderate)
chronic kidney disease stage 4 (severe)
kidney disease with likely reduction in kidney function
detachment of retinal pigment epithelium
Child-Pugh class A liver impairment
Child-Pugh class B liver impairment

Dosage

Strengths: 125 mg daily dose; 100 mg daily dose; 75 mg daily dose; 50 mg daily dose.

Cholangiocarcinoma of biliary tract

125 mg (one 100 mg capsule and one 25 mg capsule) orally once a day for 21 days on 7 days off of a 28-day cycle
Continue treatment until disease progression or unacceptable toxicity.
Select patients for the treatment of unresectable locally advanced or metastatic cholangiocarcinoma based on the presence of an FGFR2 fusion or rearrangement.
Information on FDA-approved test(s) for the detection of FGFR2 fusions or rearrangements in cholangiocarcinoma is available at: http://www.fda.gov/CompanionDiagnostics.

Renal Dose Adjustments

Mild or moderate renal dysfunction (CrCl 30 to 89 mL/min): 100 mg orally once a day for 21 days on 7 days off of a 28-day cycle
Severe renal dysfunction (CrCl 15 to less than 30 mL/min): Data not available

Liver Dose Adjustments

Mild liver dysfunction (total bilirubin greater than the upper limit of normal [ULN] to 1.5 × ULN or AST greater than ULN ): 100 mg orally once a day for 21 days on 7 days off of a 28-day cycle
Moderate liver dysfunction (total bilirubin greater than 1.5 to 3 × ULN with any AST): 75 mg orally once a day for 21 days on 7 days off of a 28-day cycle
Severe liver dysfunction (total bilirubin greater than 3 × ULN with any AST): Not established

Dose Adjustments

Dose Reduction for Adverse Reactions:

First dose reduction: 100 orally once a day
Second dose reduction: 75 mg orally once a day
Third dose reduction: 50 mg orally once a day

Dose Modification for Adverse Reactions:
Retinal Pigment Epithelial Detachment (RPED):

Continue treatment at the current dose and continue periodic ophthalmic evaluation.
If resolved within 14 days, continue treatment at the current dose.
If unresolved within 14 days, withhold treatment until resolved; then resume at previous dose or at a lower dose.

Hyperphosphatemia:
If serum phosphate greater than 5.5 to 7.5 or less mg/dL:

Continue treatment at the current dose and start or adjust the phosphate binder dose according to clinical practice.
Monitor serum phosphate weekly.
Phosphate binder dosing should be held during the week off therapy each cycle (Days 22-28) and during dose interruptions for non-hyperphosphatemia adverse events.
If serum phosphate greater than 7.5 mg/dL or single phosphate greater than 9 mg/dL independent of duration of dose of the phosphate lowering therapy:
Withhold treatment until level returns to serum phosphate of 5.5 mg/dL or less.
If serum phosphate greater than 7.5 mg/dL occurred for less than 7 days: Restart treatment at the same dose with maximal phosphate binder dosing.
If serum phosphate greater than 7.5 mg/dL for greater than 7 days or if patient had a one-time serum phosphate of greater than 9 mg/dL: Resume treatment at the next lower dose level with maximal phosphate binder dosing.
Serum phosphate with life-threatening consequences; urgent intervention indicated (e.g., dialysis): Permanently discontinue treatment.

Other Adverse Reactions:

Grade 3: Withhold dose until resolved to Grade 1 or less, then resume at the next lower dose level. If not resolved within 14 days or less, permanently discontinue treatment.
Grade 4: Permanently discontinue treatment.

Dosage Modification for Concomitant Use of Gastric Acid Reducing Agents:

It is recommended to avoid the coadministration of a proton pump inhibitor (PPI), a histamine-2 (H2) receptor antagonist, or a locally-acting antacid.
If H2-antagonist coadministration cannot be avoided it is recommended to separate the administration of this drug by 2 hours before or 10 hours after.
If locally-acting antacid coadministration cannot be avoided it is recommended to separate the administration of this drug by 2 hours before or 2 hours after.

Administration advice:

Take on an empty stomach at least 1 hour before or 2 hours after food.
Swallow capsules whole with water.
Do not crush, chew, or dissolve capsules.
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Advise lactating women not to breastfeed during therapy and for at least 1 month after the last dose.
Advise females of reproductive potential to use effective contraception during treatment with and for at least 1 month after the last dose.
Advise males that are partnered with females of reproductive potential to use effective contraception during treatment with and for at least 1 month after the last dose.
Advise patients that if a dose is missed and it has passed 4 hours or more or if vomiting, skip the dose and take the next scheduled dose at its regular time.
Advise patients that this drug may cause nail disorders.
Advise patients that this drug may cause ocular toxicity and to immediately inform their healthcare provider if they experience any visual changes.
Advise patients to use artificial tear substitutes or hydrating or lubricating eye gels to prevent or treat dry eyes.
Advise patients to inform their healthcare providers of all concomitant medications, including prescription medicines, over-the-counter drugs, and herbal products.
Advise patients that this drug may cause hyperphosphatemia and soft tissue mineralization and to immediately inform their healthcare provider of any symptoms related to acute changes in phosphate levels such as muscle cramps, numbness, or tingling around the mouth.
Advise patients to avoid grapefruit products during treatment.

Side Effects

The Most Common

diarrhea
nausea
vomiting
constipation
loss of appetite
changes in taste
heartburn or indigestion
stomach pain
sores on the lips, mouth, or throat
dry mouth and/or skin
nail disorders
hair loss
headache
fatigue
swelling of hands, feet, legs or ankles
pain in joints, arms, or legs
nose bleeds
blurred vision, floaters in the eye, seeing flashes of light, or other changes in vision
muscle cramps, numbness, or tingling around the mouth
fever, chills, or other signs of infection
blistering and peeling skin

More common

Blindness
blurred vision
confusion
constipation
decreased vision
depression
difficulty in breathing
dry eye
dry mouth
eyelash changes
headache
incoherent speech
increased urination
irregular heartbeats
loss of appetite
metallic taste
mood or mental changes
muscle cramps in the hands, arms, feet, legs, or face
muscle weakness
nausea
numbness and tingling around the mouth, fingertips, or feet
redness, swelling, or itching of the eyelid
redness, swelling, pain, or ulceration of the skin
scaling of the skin on the hands and feet
seizures
stomach cramps
thirst
tingling of the hands and feet
tremor
unusual tiredness
vomiting
weight loss

Rare

Chills
cough or hoarseness
dizziness, lightheadedness, or fainting
dry mouth
fast heartbeat
fever or chills
lower back or side pain
painful or difficult urination
rapid, shallow breathing
Acid or sour stomach
belching
bloody nose
change in taste
decreased weight
diarrhea
difficulty in moving
dry skin
hair loss, thinning of hair
heartburn
indigestion
lack or loss strength
loss of taste
muscle pain or stiffness
pain in the arms or legs
pain in the joints
redness or soreness around the fingernails or loosening of the fingernails
stomach discomfort, upset, or pain
swelling of the hands, ankles, feet, or lower legs
swelling or inflammation of the mouth

Drug Interactions

DRUG	INTERACTION
Abaloparatide	The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Infigratinib.
Abametapir	The serum concentration of Infigratinib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Infigratinib can be increased when combined with Abatacept.
Abemaciclib	The metabolism of Abemaciclib can be decreased when combined with Infigratinib.
Acalabrutinib	The metabolism of Acalabrutinib can be decreased when combined with Infigratinib.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Infigratinib.
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Infigratinib.
Acetazolamide	The metabolism of Infigratinib can be decreased when combined with Acetazolamide.
Adalimumab	The metabolism of Infigratinib can be increased when combined with Adalimumab.
Albendazole	The metabolism of Infigratinib can be decreased when combined with Albendazole.
Aldesleukin	The metabolism of Infigratinib can be decreased when combined with Aldesleukin.
Alectinib	The metabolism of Alectinib can be decreased when combined with Infigratinib.
Almasilate	The serum concentration of Infigratinib can be decreased when it is combined with Almasilate.
Alpelisib	The metabolism of Alpelisib can be decreased when combined with Infigratinib.
Aluminium	The serum concentration of Infigratinib can be decreased when it is combined with Aluminium.
Aluminium phosphate	The serum concentration of Infigratinib can be decreased when it is combined with Aluminium phosphate.
Aluminum hydroxide	The serum concentration of Infigratinib can be decreased when it is combined with Aluminum hydroxide.
Aminoglutethimide	The metabolism of Infigratinib can be increased when combined with Aminoglutethimide.
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Infigratinib.
Amiodarone	The metabolism of Infigratinib can be decreased when combined with Amiodarone.
Amobarbital	The metabolism of Infigratinib can be increased when combined with Amobarbital.
Amprenavir	The metabolism of Infigratinib can be decreased when combined with Amprenavir.
Anakinra	The metabolism of Infigratinib can be increased when combined with Anakinra.
Apalutamide	The metabolism of Infigratinib can be increased when combined with Apalutamide.
Apremilast	The metabolism of Infigratinib can be increased when combined with Apremilast.
Aprepitant	The metabolism of Infigratinib can be decreased when combined with Aprepitant.
Armodafinil	The metabolism of Infigratinib can be increased when combined with Armodafinil.
Articaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Articaine.
Asciminib	The metabolism of Infigratinib can be decreased when combined with Asciminib.
Astemizole	The metabolism of Astemizole can be decreased when combined with Infigratinib.
Asunaprevir	The metabolism of Infigratinib can be increased when combined with Asunaprevir.
Atazanavir	The metabolism of Infigratinib can be decreased when combined with Atazanavir.
Avacopan	The metabolism of Infigratinib can be decreased when combined with Avacopan.
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Infigratinib.
Axitinib	The metabolism of Axitinib can be decreased when combined with Infigratinib.
Azithromycin	The metabolism of Infigratinib can be decreased when combined with Azithromycin.
Beclomethasone	The metabolism of Infigratinib can be increased when combined with Beclomethasone dipropionate.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Benzocaine.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Benzyl alcohol.
Berotralstat	The metabolism of Infigratinib can be decreased when combined with Berotralstat.
Betamethasone	The metabolism of Infigratinib can be increased when combined with Betamethasone.
Betamethasone pho	The metabolism of Infigratinib can be increased when combined with Betamethasone phosphate.
Bexarotene	The metabolism of Infigratinib can be increased when combined with Bexarotene.
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Infigratinib.
Bifonazole	The metabolism of Infigratinib can be decreased when combined with Bifonazole.
Bimekizumab	The metabolism of Infigratinib can be increased when combined with Bimekizumab.
Bismuth subnitrate	The serum concentration of Infigratinib can be decreased when it is combined with Bismuth subnitrate.
Boceprevir	The metabolism of Infigratinib can be decreased when combined with Boceprevir.
Bortezomib	The metabolism of Bortezomib can be decreased when combined with Infigratinib.
Bosentan	The metabolism of Infigratinib can be increased when combined with Bosentan.
Bosutinib	The metabolism of Bosutinib can be decreased when combined with Infigratinib.
Brentuximab vedotin	The metabolism of Brentuximab vedotin can be decreased when combined with Infigratinib.
Brigatinib	The metabolism of Brigatinib can be decreased when combined with Infigratinib.
Budesonide	The metabolism of Infigratinib can be increased when combined with Budesonide.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Bupivacaine.
Buprenorphine	The metabolism of Infigratinib can be decreased when combined with Buprenorphine.
Busulfan	The metabolism of Busulfan can be decreased when combined with Infigratinib.
Butacaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Butacaine.
Butalbital	The metabolism of Infigratinib can be increased when combined with Butalbital.
Butamben	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Butamben.
Cabazitaxel	The metabolism of Cabazitaxel can be decreased when combined with Infigratinib.
Cabergoline	The metabolism of Cabergoline can be decreased when combined with Infigratinib.
Calcitriol	The metabolism of Infigratinib can be increased when combined with Calcitriol.
Calcium carbonate	The serum concentration of Infigratinib can be decreased when it is combined with Calcium carbonate.
Canakinumab	The metabolism of Infigratinib can be increased when combined with Canakinumab.
Candicidin	The metabolism of Infigratinib can be decreased when combined with Candicidin.
Cannabidiol	The metabolism of Infigratinib can be decreased when combined with Cannabidiol.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Capsaicin.
Carbamazepine	The metabolism of Infigratinib can be increased when combined with Carbamazepine.
Carbimazole	The therapeutic efficacy of Carbimazole can be decreased when used in combination with Infigratinib.
Cefradine	The metabolism of Infigratinib can be increased when combined with Cefradine.
Cenobamate	The serum concentration of Infigratinib can be decreased when it is combined with Cenobamate.
Cephalexin	The metabolism of Infigratinib can be decreased when combined with Cephalexin.
Ceritinib	The metabolism of Ceritinib can be decreased when combined with Infigratinib.
Cerivastatin	The metabolism of Infigratinib can be increased when combined with Cerivastatin.
Certolizumab pegol	The metabolism of Infigratinib can be increased when combined with Certolizumab pegol.
Chloramphenicol	The metabolism of Infigratinib can be decreased when combined with Chloramphenicol.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Chloroprocaine.
Chlorpromazine	The metabolism of Infigratinib can be increased when combined with Chlorpromazine.
Cimetidine	The serum concentration of Infigratinib can be decreased when it is combined with Cimetidine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Cinchocaine.
Ciprofloxacin	The metabolism of Infigratinib can be decreased when combined with Ciprofloxacin.
Cisapride	The metabolism of Infigratinib can be decreased when combined with Cisapride.
Citalopram	The metabolism of Infigratinib can be decreased when combined with Citalopram.
Clarithromycin	The metabolism of Infigratinib can be decreased when combined with Clarithromycin.
Clevidipine	The metabolism of Infigratinib can be increased when combined with Clevidipine.
Clobazam	The metabolism of Infigratinib can be increased when combined with Clobazam.
Clobetasol propio	The metabolism of Infigratinib can be increased when combined with Clobetasol propionate.
Clofazimine	The metabolism of Infigratinib can be decreased when combined with Clofazimine.
Clofibrate	The metabolism of Infigratinib can be increased when combined with Clofibrate.
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Infigratinib.
Clonidine	The metabolism of Clonidine can be decreased when combined with Infigratinib.
Clozapine	The metabolism of Infigratinib can be decreased when combined with Clozapine.
Cobicistat	The metabolism of Infigratinib can be decreased when combined with Cobicistat.
Cobimetinib	The metabolism of Cobimetinib can be decreased when combined with Infigratinib.
Cocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Cocaine.
Conivaptan	The metabolism of Infigratinib can be decreased when combined with Conivaptan.
Copanlisib	The metabolism of Copanlisib can be decreased when combined with Infigratinib.
Corticotropin	The metabolism of Infigratinib can be increased when combined with Corticotropin.
Cortisone acetate	The metabolism of Infigratinib can be increased when combined with Cortisone acetate.

You Might Also Read How Can I Treat For Facial Wrinkles With Botulinum Toxin

Crizotinib	The metabolism of Infigratinib can be decreased when combined with Crizotinib.
Curcumin	The metabolism of Infigratinib can be decreased when combined with Curcumin.
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Infigratinib.
Cyclosporine	The metabolism of Infigratinib can be decreased when combined with Cyclosporine.
Cyproterone acetate	The metabolism of Infigratinib can be decreased when combined with Cyproterone acetate.
Dabrafenib	The serum concentration of Infigratinib can be decreased when it is combined with Dabrafenib.
Dacomitinib	The metabolism of Dacomitinib can be decreased when combined with Infigratinib.
Dalfopristin	The metabolism of Infigratinib can be decreased when combined with Dalfopristin.
Danazol	The metabolism of Infigratinib can be decreased when combined with Danazol.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Infigratinib.
Darunavir	The metabolism of Infigratinib can be decreased when combined with Darunavir.
Dasatinib	The metabolism of Dasatinib can be decreased when combined with Infigratinib.
Daunorubicin	The metabolism of Infigratinib can be decreased when combined with Daunorubicin.
Deferasirox	The metabolism of Infigratinib can be increased when combined with Deferasirox.
Deflazacort	The metabolism of Infigratinib can be increased when combined with Deflazacort.
Delavirdine	The metabolism of Infigratinib can be decreased when combined with Delavirdine.
Desipramine	The metabolism of Infigratinib can be decreased when combined with Desipramine.
Desvenlafaxine	The metabolism of Infigratinib can be decreased when combined with Desvenlafaxine.
Dexamethasone	The metabolism of Infigratinib can be increased when combined with Dexamethasone.
Dexamethasone	The metabolism of Infigratinib can be increased when combined with Dexamethasone acetate.
Dexlansoprazole	The serum concentration of Infigratinib can be decreased when it is combined with Dexlansoprazole.
Dextropropoxyphene	The metabolism of Infigratinib can be decreased when combined with Dextropropoxyphene.
Dicloxacillin	The metabolism of Infigratinib can be increased when combined with Dicloxacillin.
Diethylstilbestrol	The metabolism of Infigratinib can be decreased when combined with Diethylstilbestrol.
Difluocortolone	The metabolism of Infigratinib can be increased when combined with Difluocortolone.
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Infigratinib.
Dihydroergocornine	The metabolism of Infigratinib can be decreased when combined with Dihydroergocornine.
Dihydroergocristine	The metabolism of Dihydroergocristine can be decreased when combined with Infigratinib.
Dihydroergotamine	The metabolism of Dihydroergotamine can be decreased when combined with Infigratinib.
Diltiazem	The metabolism of Infigratinib can be decreased when combined with Diltiazem.
Dimethyl sulfoxide	The metabolism of Infigratinib can be decreased when combined with Dimethyl sulfoxide.
Diosmin	The metabolism of Infigratinib can be decreased when combined with Diosmin.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Diphenhydramine.
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Infigratinib.
Dofetilide	The metabolism of Dofetilide can be decreased when combined with Infigratinib.
Doxazosin	The metabolism of Infigratinib can be decreased when combined with Doxazosin.
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Infigratinib.
Dronedarone	The metabolism of Infigratinib can be decreased when combined with Dronedarone.
Drospirenone	The metabolism of Infigratinib can be decreased when combined with Drospirenone.
Duvelisib	The metabolism of Duvelisib can be decreased when combined with Infigratinib.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Dyclonine.
Ebastine	The metabolism of Infigratinib can be decreased when combined with Ebastine.
Echinacea	The metabolism of Infigratinib can be increased when combined with Echinacea.
Econazole	The metabolism of Infigratinib can be decreased when combined with Econazole.
Efavirenz	The metabolism of Infigratinib can be decreased when combined with Efavirenz.
Elexacaftor	The metabolism of Elexacaftor can be decreased when combined with Infigratinib.
Elvitegravir	The metabolism of Infigratinib can be decreased when combined with Elvitegravir.
Emapalumab	The metabolism of Infigratinib can be increased when combined with Emapalumab.
Enasidenib	The metabolism of Enasidenib can be decreased when combined with Infigratinib.
Entrectinib	The metabolism of Entrectinib can be decreased when combined with Infigratinib.
Enzalutamide	The metabolism of Infigratinib can be increased when combined with Enzalutamide.
Epinephrine	The metabolism of Infigratinib can be decreased when combined with Epinephrine.
Erdafitinib	The metabolism of Erdafitinib can be decreased when combined with Infigratinib.
Ergotamine	The metabolism of Infigratinib can be decreased when combined with Ergotamine.
Erlotinib	The metabolism of Erlotinib can be decreased when combined with Infigratinib.
Erythromycin	The metabolism of Infigratinib can be decreased when combined with Erythromycin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Infigratinib.
Esketamine	The metabolism of Infigratinib can be increased when combined with Esketamine.
Eslicarbazepine	The metabolism of Infigratinib can be increased when combined with Eslicarbazepine.
Eslicarbazepine	The metabolism of Infigratinib can be increased when combined with Eslicarbazepine acetate.
Esomeprazole	The serum concentration of Infigratinib can be decreased when it is combined with Esomeprazole.
Estetrol	The metabolism of Estetrol can be decreased when combined with Infigratinib.
Estradiol acetate	The metabolism of Infigratinib can be increased when combined with Estradiol acetate.
Estradiol benzoate	The metabolism of Infigratinib can be increased when combined with Estradiol benzoate.
Estradiol cypionate	The metabolism of Infigratinib can be increased when combined with Estradiol cypionate.
Estradiol dienanthate	The metabolism of Infigratinib can be increased when combined with Estradiol dienanthate.
Estradiol valerate	The metabolism of Infigratinib can be increased when combined with Estradiol valerate.
Etanercept	The metabolism of Infigratinib can be increased when combined with Etanercept.
Ethambutol	The metabolism of Infigratinib can be decreased when combined with Ethambutol.
Ethanol	The metabolism of Infigratinib can be increased when combined with Ethanol.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Etidocaine.
Etoposide	The metabolism of Etoposide can be decreased when combined with Infigratinib.
Etoricoxib	The metabolism of Infigratinib can be decreased when combined with Etoricoxib.
Etravirine	The metabolism of Infigratinib can be increased when combined with Etravirine.
Everolimus	The metabolism of Everolimus can be decreased when combined with Infigratinib.
Famotidine	The serum concentration of Infigratinib can be decreased when it is combined with Famotidine.
Felbamate	The metabolism of Infigratinib can be increased when combined with Felbamate.
Fenofibrate	The metabolism of Infigratinib can be decreased when combined with Fenofibrate.
Fexinidazole	The metabolism of Infigratinib can be decreased when combined with Fexinidazole.
Flucloxacillin	The metabolism of Infigratinib can be increased when combined with Flucloxacillin.
Fluconazole	The metabolism of Infigratinib can be decreased when combined with Fluconazole.
Flunisolide	The metabolism of Infigratinib can be increased when combined with Flunisolide.
Fluocinolone	The metabolism of Infigratinib can be increased when combined with Fluocinolone acetonide.
Fluocinonide	The metabolism of Infigratinib can be increased when combined with Fluocinonide.
Fluocortolone	The metabolism of Infigratinib can be increased when combined with Fluocortolone.
Fluoxetine	The metabolism of Infigratinib can be decreased when combined with Fluoxetine.
Fluticasone	The metabolism of Infigratinib can be increased when combined with Fluticasone.
Fluticasone pro	The metabolism of Infigratinib can be decreased when combined with Fluticasone propionate.
Fluvoxamine	The metabolism of Infigratinib can be decreased when combined with Fluvoxamine.
Follitropin	The therapeutic efficacy of Follitropin can be decreased when used in combination with Infigratinib.
Formestane	The metabolism of Infigratinib can be increased when combined with Formestane.
Fosamprenavir	The metabolism of Infigratinib can be decreased when combined with Fosamprenavir.
Fosaprepitant	The metabolism of Infigratinib can be increased when combined with Fosaprepitant.
Fosnetupitant	The metabolism of Infigratinib can be decreased when combined with Fosnetupitant.
Fosphenytoin	The metabolism of Infigratinib can be increased when combined with Fosphenytoin.
Fostamatinib	The metabolism of Infigratinib can be decreased when combined with Fostamatinib.
Fusidic acid	The metabolism of Infigratinib can be decreased when combined with Fusidic acid.
Gilteritinib	The metabolism of Gilteritinib can be decreased when combined with Infigratinib.
Ginkgo biloba	The metabolism of Infigratinib can be decreased when combined with Ginkgo biloba.

You Might Also Read Etanercept; Uses, Dosage, Side Effects, Drug Interactions

Glecaprevir	The metabolism of Infigratinib can be decreased when combined with Glecaprevir.
Glyburide	The metabolism of Infigratinib can be decreased when combined with Glyburide.
Glycerol pheny	The metabolism of Infigratinib can be increased when combined with Glycerol phenylbutyrate.
Golimumab	The metabolism of Infigratinib can be increased when combined with Golimumab.
Griseofulvin	The metabolism of Infigratinib can be increased when combined with Griseofulvin.
Haloperidol	The metabolism of Infigratinib can be decreased when combined with Haloperidol.
Hydralazine	The metabolism of Infigratinib can be decreased when combined with Hydralazine.
Hydrocortamate	The metabolism of Infigratinib can be increased when combined with Hydrocortamate.
Hydrocortisone	The metabolism of Infigratinib can be increased when combined with Hydrocortisone.
Hydrocortisone acetate	The metabolism of Infigratinib can be increased when combined with Hydrocortisone acetate.
Hydrocortisone but	The metabolism of Infigratinib can be increased when combined with Hydrocortisone butyrate.
Hydrocortisone succ	The metabolism of Infigratinib can be increased when combined with Hydrocortisone succinate.
Hydrotalcite	The serum concentration of Infigratinib can be decreased when it is combined with Hydrotalcite.
Idelalisib	The metabolism of Idelalisib can be decreased when combined with Infigratinib.
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Infigratinib.
Imatinib	The metabolism of Infigratinib can be decreased when combined with Imatinib.
Indinavir	The metabolism of Infigratinib can be decreased when combined with Indinavir.
Infliximab	The metabolism of Infigratinib can be increased when combined with Infliximab.
Irbesartan	The metabolism of Infigratinib can be decreased when combined with Irbesartan.
Irinotecan	The metabolism of Irinotecan can be decreased when combined with Infigratinib.
Isavuconazole	The metabolism of Infigratinib can be decreased when combined with Isavuconazole.
Isavuconazonium	The metabolism of Infigratinib can be decreased when combined with Isavuconazonium.
Isoniazid	The metabolism of Infigratinib can be decreased when combined with Isoniazid.
Isradipine	The metabolism of Infigratinib can be decreased when combined with Isradipine.
Itraconazole	The metabolism of Infigratinib can be decreased when combined with Itraconazole.
Ivacaftor	The metabolism of Infigratinib can be decreased when combined with Ivacaftor.
Ivosidenib	The metabolism of Infigratinib can be increased when combined with Ivosidenib.
Ixabepilone	The metabolism of Ixabepilone can be decreased when combined with Infigratinib.
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Infigratinib.
Ketazolam	The metabolism of Infigratinib can be decreased when combined with Ketazolam.
Ketoconazole	The metabolism of Infigratinib can be decreased when combined with Ketoconazole.
Lacosamide	The metabolism of Infigratinib can be decreased when combined with Lacosamide.
Lanreotide	The metabolism of Infigratinib can be decreased when combined with Lanreotide.
Lansoprazole	The serum concentration of Infigratinib can be decreased when it is combined with Lansoprazole.
Lapatinib	The metabolism of Infigratinib can be decreased when combined with Lapatinib.
Lefamulin	The metabolism of Lefamulin can be decreased when combined with Infigratinib.
Lesinurad	The metabolism of Infigratinib can be increased when combined with Lesinurad.
Letermovir	The metabolism of Infigratinib can be decreased when combined with Letermovir.
Levacetylmethadol	The metabolism of Levacetylmethadol can be decreased when combined with Infigratinib.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Levobupivacaine.
Levoketoconazole	The metabolism of Infigratinib can be decreased when combined with Levoketoconazole.
Levothyroxine	The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Infigratinib.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Lidocaine.
Linagliptin	The metabolism of Infigratinib can be decreased when combined with Linagliptin.
Liothyronine	The therapeutic efficacy of Liothyronine can be decreased when used in combination with Infigratinib.
Liotrix	The therapeutic efficacy of Liotrix can be decreased when used in combination with Infigratinib.
Lomitapide	The metabolism of Lomitapide can be decreased when combined with Infigratinib.
Lonafarnib	The metabolism of Infigratinib can be decreased when combined with Lonafarnib.
Lopinavir	The metabolism of Infigratinib can be decreased when combined with Lopinavir.
Lorlatinib	The metabolism of Infigratinib can be increased when combined with Lorlatinib.
Losartan	The metabolism of Infigratinib can be decreased when combined with Losartan.
Lovastatin	The metabolism of Infigratinib can be decreased when combined with Lovastatin.
Luliconazole	The metabolism of Infigratinib can be decreased when combined with Luliconazole.
Lumacaftor	The metabolism of Infigratinib can be increased when combined with Lumacaftor.
Magaldrate	The serum concentration of Infigratinib can be decreased when it is combined with Magaldrate.
Magnesium carbonate	The serum concentration of Infigratinib can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxide	The serum concentration of Infigratinib can be decreased when it is combined with Magnesium hydroxide.
Magnesium oxide	The serum concentration of Infigratinib can be decreased when it is combined with Magnesium oxide.
Magnesium silicate	The serum concentration of Infigratinib can be decreased when it is combined with Magnesium silicate.
Magnesium trisilicate	The serum concentration of Infigratinib can be decreased when it is combined with Magnesium trisilicate.
Manidipine	The metabolism of Infigratinib can be decreased when combined with Manidipine.
Mavacamten	The serum concentration of Infigratinib can be decreased when it is combined with Mavacamten.
Medroxyprogesterone	The metabolism of Infigratinib can be increased when combined with Medroxyprogesterone acetate.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Meloxicam.
Meperidine	The metabolism of Infigratinib can be decreased when combined with Meperidine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Mepivacaine.
Meprednisone	The metabolism of Infigratinib can be increased when combined with Meprednisone.
Methadone	The metabolism of Infigratinib can be decreased when combined with Methadone.
Methantheline	The serum concentration of Infigratinib can be decreased when it is combined with Methantheline.
Methimazole	The metabolism of Infigratinib can be decreased when combined with Methimazole.
Methotrexate	The metabolism of Methotrexate can be decreased when combined with Infigratinib.
Methoxy poly	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Infigratinib.
Methylene blue	The metabolism of Infigratinib can be decreased when combined with Methylene blue.
Methylergometrine	The metabolism of Infigratinib can be decreased when combined with Methylergometrine.
Methylphenobarbital	The metabolism of Infigratinib can be increased when combined with Methylphenobarbital.
Methylprednisolone	The metabolism of Infigratinib can be increased when combined with Methylprednisolone.
Methylprednisone	The metabolism of Methylprednisone can be decreased when combined with Infigratinib.
Methysergide	The metabolism of Infigratinib can be decreased when combined with Methysergide.
Metreleptin	The metabolism of Infigratinib can be increased when combined with Metreleptin.
Metronidazole	The metabolism of Infigratinib can be decreased when combined with Metronidazole.
Metyrapone	The metabolism of Infigratinib can be increased when combined with Metyrapone.
Miconazole	The metabolism of Infigratinib can be decreased when combined with Miconazole.
Midazolam	The metabolism of Infigratinib can be decreased when combined with Midazolam.
Midostaurin	The metabolism of Infigratinib can be decreased when combined with Midostaurin.
Mifepristone	The metabolism of Infigratinib can be increased when combined with Mifepristone.
Milnacipran	The metabolism of Infigratinib can be decreased when combined with Milnacipran.
Miocamycin	The metabolism of Infigratinib can be decreased when combined with Miocamycin.
Mirtazapine	The metabolism of Infigratinib can be decreased when combined with Mirtazapine.
Mitapivat	The metabolism of Infigratinib can be increased when combined with Mitapivat.
Mitotane	The metabolism of Infigratinib can be increased when combined with Mitotane.
Modafinil	The metabolism of Infigratinib can be increased when combined with Modafinil.
Mometasone	The metabolism of Infigratinib can be increased when combined with Mometasone furoate.
Nafcillin	The metabolism of Infigratinib can be increased when combined with Nafcillin.
Nefazodone	The metabolism of Infigratinib can be decreased when combined with Nefazodone.
Nelfinavir	The metabolism of Infigratinib can be decreased when combined with Nelfinavir.
Neratinib	The metabolism of Neratinib can be decreased when combined with Infigratinib.
Netupitant	The metabolism of Infigratinib can be decreased when combined with Netupitant.
Niacin	The metabolism of Infigratinib can be decreased when combined with Niacin.
Nicardipine	The metabolism of Infigratinib can be decreased when combined with Nicardipine.
Nilotinib	The metabolism of Infigratinib can be decreased when combined with Nilotinib.

Nilvadipine	The metabolism of Infigratinib can be decreased when combined with Nilvadipine.
Nintedanib	The metabolism of Infigratinib can be decreased when combined with Nintedanib.
Nizatidine	The serum concentration of Infigratinib can be decreased when it is combined with Nizatidine.
Norethisterone	The metabolism of Infigratinib can be decreased when combined with Norethisterone.
Norgestimate	The metabolism of Infigratinib can be increased when combined with Norgestimate.
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Infigratinib.
Noscapine	The metabolism of Infigratinib can be decreased when combined with Noscapine.
Octreotide	The metabolism of Infigratinib can be decreased when combined with Octreotide.
Olaparib	The metabolism of Olaparib can be decreased when combined with Infigratinib.
Omeprazole	The serum concentration of Infigratinib can be decreased when it is combined with Omeprazole.
Oritavancin	The metabolism of Infigratinib can be increased when combined with Oritavancin.
Orphenadrine	The metabolism of Infigratinib can be decreased when combined with Orphenadrine.
Osilodrostat	The metabolism of Infigratinib can be decreased when combined with Osilodrostat.
Osimertinib	The metabolism of Osimertinib can be decreased when combined with Infigratinib.
Oxcarbazepine	The metabolism of Infigratinib can be increased when combined with Oxcarbazepine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Oxetacaine.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Oxybuprocaine.
Oxybutynin	The metabolism of Infigratinib can be decreased when combined with Oxybutynin.
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Infigratinib.
Pacritinib	The metabolism of Infigratinib can be decreased when combined with Pacritinib.
Palbociclib	The metabolism of Palbociclib can be decreased when combined with Infigratinib.
Panobinostat	The metabolism of Panobinostat can be decreased when combined with Infigratinib.
Pantoprazole	The serum concentration of Infigratinib can be decreased when it is combined with Pantoprazole.
Parathyroid hor	The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Infigratinib.
Pasireotide	The metabolism of Infigratinib can be decreased when combined with Pasireotide.
Pazopanib	The metabolism of Pazopanib can be decreased when combined with Infigratinib.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Infigratinib.
Pentobarbital	The metabolism of Infigratinib can be increased when combined with Pentobarbital.
Perampanel	The metabolism of Infigratinib can be increased when combined with Perampanel.
Pexidartinib	The metabolism of Pexidartinib can be decreased when combined with Infigratinib.
Phenobarbital	The metabolism of Infigratinib can be increased when combined with Phenobarbital.
Phenol	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Phenol.
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Infigratinib.
Phenylbutazone	The metabolism of Infigratinib can be increased when combined with Phenylbutazone.
Phenytoin	The metabolism of Infigratinib can be increased when combined with Phenytoin.
Pimavanserin	The metabolism of Infigratinib can be decreased when combined with Pimavanserin.
Pimozide	The metabolism of Pimozide can be decreased when combined with Infigratinib.
Piperaquine	The metabolism of Infigratinib can be decreased when combined with Piperaquine.
Pitolisant	The serum concentration of Infigratinib can be decreased when it is combined with Pitolisant.
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Infigratinib.
Ponatinib	The metabolism of Ponatinib can be decreased when combined with Infigratinib.
Posaconazole	The metabolism of Infigratinib can be decreased when combined with Posaconazole.
Potassium Iodide	The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Infigratinib.
Potassium perchlorate	The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Infigratinib.
Pralsetinib	The metabolism of Infigratinib can be increased when combined with Pralsetinib.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Pramocaine.
Prednisolone	The metabolism of Infigratinib can be increased when combined with Prednisolone.
Prednisolone acetate	The metabolism of Infigratinib can be increased when combined with Prednisolone acetate.
Prednisolone phosp	The metabolism of Infigratinib can be increased when combined with Prednisolone phosphate.
Prednisone acetate	The metabolism of Infigratinib can be increased when combined with Prednisone acetate.
Pretomanid	The metabolism of Infigratinib can be decreased when combined with Pretomanid.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Prilocaine.
Primaquine	The metabolism of Infigratinib can be decreased when combined with Primaquine.
Primidone	The metabolism of Infigratinib can be increased when combined with Primidone.
Probenecid	The metabolism of Infigratinib can be increased when combined with Probenecid.
Procaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Procaine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Proparacaine.
Propofol	The metabolism of Infigratinib can be decreased when combined with Propofol.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Propoxycaine.
Propylthiouracil	The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Infigratinib.
Protirelin	The therapeutic efficacy of Protirelin can be decreased when used in combination with Infigratinib.
Quinidine	The metabolism of Quinidine can be decreased when combined with Infigratinib.
Quinine	The metabolism of Infigratinib can be increased when combined with Quinine.
Quinupristin	The metabolism of Infigratinib can be decreased when combined with Quinupristin.
Rabeprazole	The serum concentration of Infigratinib can be decreased when it is combined with Rabeprazole.
Raloxifene	The metabolism of Infigratinib can be decreased when combined with Raloxifene.
Ranitidine	The serum concentration of Infigratinib can be decreased when it is combined with Ranitidine.
Ranolazine	The metabolism of Infigratinib can be decreased when combined with Ranolazine.
Regorafenib	The metabolism of Regorafenib can be decreased when combined with Infigratinib.
Remdesivir	The metabolism of Infigratinib can be decreased when combined with Remdesivir.
Ribociclib	The metabolism of Infigratinib can be decreased when combined with Ribociclib.
Rifabutin	The metabolism of Infigratinib can be increased when combined with Rifabutin.
Rifampicin	The metabolism of Infigratinib can be increased when combined with Rifampicin.
Rifamycin	The metabolism of Infigratinib can be increased when combined with Rifamycin.
Rifapentine	The metabolism of Infigratinib can be increased when combined with Rifapentine.
Rilonacept	The metabolism of Infigratinib can be increased when combined with Rilonacept.
Rilpivirine	The metabolism of Infigratinib can be decreased when combined with Rilpivirine.
Rimexolone	The metabolism of Infigratinib can be increased when combined with Rimexolone.
Ritonavir	The metabolism of Infigratinib can be decreased when combined with Ritonavir.
Rofecoxib	The metabolism of Infigratinib can be increased when combined with Rofecoxib.
Roflumilast	The metabolism of Infigratinib can be decreased when combined with Roflumilast.
Romidepsin	The metabolism of Romidepsin can be decreased when combined with Infigratinib.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Ropivacaine.
Rosuvastatin	The metabolism of Infigratinib can be decreased when combined with Rosuvastatin.
Roxithromycin	The metabolism of Infigratinib can be decreased when combined with Roxithromycin.
Rucaparib	The metabolism of Infigratinib can be decreased when combined with Rucaparib.
Rufinamide	The metabolism of Infigratinib can be increased when combined with Rufinamide.
Ruxolitinib	The metabolism of Ruxolitinib can be decreased when combined with Infigratinib.
Salmon calcitonin	The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Infigratinib.
Saquinavir	The metabolism of Infigratinib can be decreased when combined with Saquinavir.
Sarilumab	The metabolism of Infigratinib can be increased when combined with Sarilumab.
Satralizumab	The serum concentration of Infigratinib can be decreased when it is combined with Satralizumab.
Secobarbital	The metabolism of Infigratinib can be increased when combined with Secobarbital.
Secukinumab	The metabolism of Infigratinib can be increased when combined with Secukinumab.
Siltuximab	The metabolism of Infigratinib can be increased when combined with Siltuximab.
Simeprevir	The metabolism of Infigratinib can be decreased when combined with Simeprevir.
Siponimod	The metabolism of Siponimod can be decreased when combined with Infigratinib.
Sirolimus	The metabolism of Sirolimus can be decreased when combined with Infigratinib.
Sitaxentan	The metabolism of Infigratinib can be decreased when combined with Sitaxentan.
Sodium bicarb	The serum concentration of Infigratinib can be decreased when it is combined with Sodium bicarbonate.

You Might Also Read Citalopram; Uses, Dosage, Side Effects, Interactions, Pregnancy

Sodium zirconium	The serum concentration of Infigratinib can be decreased when it is combined with Sodium zirconium cyclosilicate.
Somatostatin	The metabolism of Infigratinib can be decreased when combined with Somatostatin.
Somatrogon	The metabolism of Infigratinib can be increased when combined with Somatrogon.
Sonidegib	The metabolism of Sonidegib can be decreased when combined with Infigratinib.
Sorafenib	The metabolism of Sorafenib can be decreased when combined with Infigratinib.
Sotorasib	The serum concentration of Infigratinib can be decreased when it is combined with Sotorasib.
St. John’s Wort	The metabolism of Infigratinib can be increased when combined with St. John’s Wort.
Stiripentol	The metabolism of Infigratinib can be decreased when combined with Stiripentol.
Sulfamethoxazole	The metabolism of Infigratinib can be decreased when combined with Sulfamethoxazole.
Sulfinpyrazone	The metabolism of Infigratinib can be increased when combined with Sulfinpyrazone.
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Infigratinib.
Suvorexant	The metabolism of Infigratinib can be decreased when combined with Suvorexant.
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Infigratinib.
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Infigratinib.
Tasimelteon	The metabolism of Infigratinib can be decreased when combined with Tasimelteon.
Tazemetostat	The metabolism of Tazemetostat can be decreased when combined with Infigratinib.
Tecovirimat	The metabolism of Infigratinib can be increased when combined with Tecovirimat.
Telaprevir	The metabolism of Infigratinib can be decreased when combined with Telaprevir.
Telithromycin	The metabolism of Infigratinib can be decreased when combined with Telithromycin.
Telotristat ethyl	The serum concentration of Infigratinib can be decreased when it is combined with Telotristat ethyl.
Temsirolimus	The metabolism of Temsirolimus can be decreased when combined with Infigratinib.
Teniposide	The metabolism of Teniposide can be decreased when combined with Infigratinib.
Tenofovir alafe	The metabolism of Infigratinib can be decreased when combined with Tenofovir alafenamide.
Terbinafine	The metabolism of Infigratinib can be increased when combined with Terbinafine.
Terfenadine	The metabolism of Infigratinib can be decreased when combined with Terfenadine.
Teriparatide	The therapeutic efficacy of Teriparatide can be decreased when used in combination with Infigratinib.
Testosterone	The metabolism of Infigratinib can be increased when combined with Testosterone.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Infigratinib is combined with Tetracaine.
Tetracycline	The metabolism of Infigratinib can be decreased when combined with Tetracycline.
Theophylline	The metabolism of Theophylline can be decreased when combined with Infigratinib.
Thiamylal	The metabolism of Infigratinib can be increased when combined with Thiamylal.
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Infigratinib.
Thyroid, porcine	The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Infigratinib.
Thyrotropin alfa	The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Infigratinib.
Ticagrelor	The metabolism of Infigratinib can be decreased when combined with Ticagrelor.
Tioconazole	The metabolism of Infigratinib can be decreased when combined with Tioconazole.
Tipranavir	The metabolism of Infigratinib can be decreased when combined with Tipranavir.
Tocilizumab	The metabolism of Infigratinib can be increased when combined with Tocilizumab.
Tolvaptan	The metabolism of Tolvaptan can be decreased when combined with Infigratinib.
Topiramate	The metabolism of Infigratinib can be increased when combined with Topiramate.
Trabectedin	The metabolism of Trabectedin can be decreased when combined with Infigratinib.
Trastuzumab emta	The metabolism of Trastuzumab emtansine can be decreased when combined with Infigratinib.
Triamcinolone	The metabolism of Infigratinib can be increased when combined with Triamcinolone.
Triclabendazole	The metabolism of Infigratinib can be decreased when combined with Triclabendazole.
Troglitazone	The metabolism of Infigratinib can be increased when combined with Troglitazone.
Troleandomycin	The metabolism of Infigratinib can be decreased when combined with Troleandomycin.
Tucatinib	The metabolism of Tucatinib can be decreased when combined with Infigratinib.
Valproic acid	The metabolism of Infigratinib can be decreased when combined with Valproic acid.
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Infigratinib.
Vemurafenib	The metabolism of Vemurafenib can be decreased when combined with Infigratinib.
Venetoclax	The metabolism of Infigratinib can be decreased when combined with Venetoclax.
Verapamil	The metabolism of Infigratinib can be decreased when combined with Verapamil.
Viloxazine	The metabolism of Infigratinib can be decreased when combined with Viloxazine.
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Infigratinib.
Vincristine	The metabolism of Vincristine can be decreased when combined with Infigratinib.
Vindesine	The metabolism of Vindesine can be decreased when combined with Infigratinib.
Vinflunine	The metabolism of Vinflunine can be decreased when combined with Infigratinib.
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Infigratinib.
Vitamin E	The metabolism of Infigratinib can be increased when combined with Vitamin E.
Vonoprazan	The serum concentration of Infigratinib can be decreased when it is combined with Vonoprazan.
Vorapaxar	The metabolism of Infigratinib can be decreased when combined with Vorapaxar.
Voriconazole	The metabolism of Infigratinib can be decreased when combined with Voriconazole.
Warfarin	The metabolism of Warfarin can be decreased when combined with Infigratinib.
Zafirlukast	The metabolism of Infigratinib can be decreased when combined with Zafirlukast.
Zanubrutinib	The metabolism of Zanubrutinib can be decreased when combined with Infigratinib.
Zimelidine	The metabolism of Infigratinib can be decreased when combined with Zimelidine.
Ziprasidone	The metabolism of Infigratinib can be decreased when combined with Ziprasidone.
Zuclopenthixol	The metabolism of Infigratinib can be decreased when combined with Zuclopenthixol.

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

Based on findings in animal studies and its mechanism of action TRUSELTIQ can cause fetal harm or loss of pregnancy when administered to a pregnant woman [see Clinical Pharmacology (13.1)]. There are no available data on the use of TRUSELTIQ during pregnancy. Oral administration of infigratinib to pregnant animals during the period of organogenesis at maternal exposures below the human exposure at the clinical dose of 125 mg resulted in malformations, fetal growth retardation, and embryo-fetal death (see Data). Advise pregnant
women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in
clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

There are no data on the presence of infigratinib or its metabolites in human milk, or their effects on either the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children from TRUSELTIQ, advise women not to breastfeed during treatment and for 1 month after the final dose.

How should this medicine be used?

Infigratinib comes as a capsule to take by mouth. It is usually taken once daily on an empty stomach (at least 1 hour before or at least 2 hours after food) for the first 21 days of a 28-day cycle. The cycle may be repeated as recommended by your doctor. Take infigratinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take infigratinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Swallow the capsules whole with a glass of water; do not split, chew, dissolve, or open them.

If you vomit after taking infigratinib, do not take another dose. Continue your regular dosing schedule.

Your doctor may decrease your dose or temporarily or permanently stop your treatment if you experience certain side effects. This depends on how well the medication works for you and the side effects you experience. Be sure to tell your doctor how you are feeling during your treatment with infigratinib.

Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient.

Other uses for this medicine

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

What special precautions should I follow?

Before taking infigratinib,

tell your doctor and pharmacist if you are allergic to infigratinib, any other medications, or any of the ingredients in infigratinib capsules. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: itraconazole (Sporanox, Tolsura); proton-pump inhibitors, such as lansoprazole (Prevacid), omeprazole (Prilosec), and pantoprazole (Protonix); and rifampin (Rifadin, Rimactane, in Rifamate). Many other medications may also interact with infigratinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
if you are taking antacids, such as aluminum hydroxide/magnesium hydroxide (Maalox), calcium carbonate (Tums), or calcium carbonate and magnesium (Rolaids), take infigratinib 2 hours before or 2 hours after you take the antacid. If you are taking H₂ blockers, such as cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), and ranitidine (Zantac), take infigratinib 2 hours before or 10 hours after you take the H₂ blocker.
tell your doctor if you have vision or eye problems or if you have or ever had liver or kidney problems.
tell your doctor if you are pregnant, plan to become pregnant, or if you plan on fathering a child. If you are female, you will need to take a pregnancy test before you start treatment and use birth control to prevent pregnancy during your treatment and for at least 1 month after your final dose. If you are a male, you and your partner should use birth control during your treatment and for 1 month after your final dose. Talk to your doctor about birth control methods that you can use during your treatment. If you or your partner become pregnant while taking infigratinib, call your doctor immediately. Infigratinib may harm the fetus.
tell your doctor if you are breastfeeding. You should not breastfeed while you are taking infigratinib and for 1 month after your final dose.
you should know that this medication may cause dry eyes. Your doctor may tell you to use artificial tears or lubricant eye drops during your treatment with infigratinib.

References